Company intelligence / Profile preview
Cell2in
Seoul, Seoul, South Koreacell2in.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Cell2in has developed the world’s first real-time cell quality measurement platform (FreSHtracer), validated in multiple peer-reviewed journals and patents, with an IND filed for asthma. The company demonstrates improved cell therapy quality, including validated results with partners such as Cellect Biotechnology [1][4][7].
- Therapeutic areas
- PulmonologyImmunologyRheumatology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Cellect Biotechnology (collaborative validation of stem cell expansion and quality improvement)Institut Pasteur Korea (certification for FreSHtracer technology)
Beyond the preview
Go deeper on Cell2in.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cell2in.